Background: Actinium-225 (²²⁵Ac, t₁/₂ = 9.9 d) is a promising candidate radionuclide for use in targeted alpha therapy (TAT), though the currently limited global supply has hindered the development of a suitable Ac-chelating ligand and ²²⁵Ac-radiopharmaceuticals towards the clinic. We at TRIUMF have leveraged our Isotope Separation On-Line (ISOL) facility to produce ²²⁵Ac and use the resulting radioactivity to screen a number of potential ²²⁵Ac-radiopharmaceutical compounds. Results: MBq quantities of ²²⁵Ac and parent radium-225 (²²⁵Ra, t₁/₂ = 14.8 d) were produced and separated using solid phase extraction DGA resin, resulting in a radiochemically pure ²²⁵Ac...
Purpose: The development of a prostate-specific membrane antigen (PSMA)-ligand for labeling with dif...
This thesis presents studies on a class of acyclic (open chain) chelating ligands based on the picol...
One promising treatment option for metastatic castration-resistant prostate cancer is systemic radio...
Background: Actinium-225 (²²⁵Ac, t₁/₂ = 9.9 d) is a promising candidate radionuclid...
Background Actinium-225 (225Ac, t1/2 = 9.9 d) is a promising candidate radionuclide for us...
Actinium-225 (225Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although 225A...
Actinium-225 (Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although Ac labe...
Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly h...
Radiometal-based pharmaceuticals have emerged as powerful clinical tools which can achieve both diag...
[Introduction] Ac-225 (T1/2 = 10 d) is regarded as a promising alpha emitter for the targeted alpha ...
Introduction: Patients with metastatic castration resistant prostate cancer (mCRPC) have a poor prog...
Introduction: Alpha particle emitting isotopes are of considerable interest for radionuclide therapy...
The successful application of alpha-emitters in targeted alpha therapy (TAT) goes together with deve...
The use of alpha emitters as a therapeutic nuclide for cancer therapy becomes more interesting in th...
International audienceAmong all existing radionuclides, only a few are of interest for therapeutic a...
Purpose: The development of a prostate-specific membrane antigen (PSMA)-ligand for labeling with dif...
This thesis presents studies on a class of acyclic (open chain) chelating ligands based on the picol...
One promising treatment option for metastatic castration-resistant prostate cancer is systemic radio...
Background: Actinium-225 (²²⁵Ac, t₁/₂ = 9.9 d) is a promising candidate radionuclid...
Background Actinium-225 (225Ac, t1/2 = 9.9 d) is a promising candidate radionuclide for us...
Actinium-225 (225Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although 225A...
Actinium-225 (Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although Ac labe...
Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly h...
Radiometal-based pharmaceuticals have emerged as powerful clinical tools which can achieve both diag...
[Introduction] Ac-225 (T1/2 = 10 d) is regarded as a promising alpha emitter for the targeted alpha ...
Introduction: Patients with metastatic castration resistant prostate cancer (mCRPC) have a poor prog...
Introduction: Alpha particle emitting isotopes are of considerable interest for radionuclide therapy...
The successful application of alpha-emitters in targeted alpha therapy (TAT) goes together with deve...
The use of alpha emitters as a therapeutic nuclide for cancer therapy becomes more interesting in th...
International audienceAmong all existing radionuclides, only a few are of interest for therapeutic a...
Purpose: The development of a prostate-specific membrane antigen (PSMA)-ligand for labeling with dif...
This thesis presents studies on a class of acyclic (open chain) chelating ligands based on the picol...
One promising treatment option for metastatic castration-resistant prostate cancer is systemic radio...